Prime Medicine, Inc.
NASDAQ:PRMEBiotechnology
-$0.04 today
- Market cap
- $694.94M
- Beta
- 2.31
- P/E (TTM)
- -2.8
- EPS (TTM)
- -$1.12
Volume 4.62M
Average 2.47M
PRME Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Prime Medicine, Inc.NASDAQ: PRME
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income declines year over year
Q1 FY2026 net income of $49.12M (cash outflow) fell 5.3% year over year, behind the -1.8% change in trailing-twelve-month net income. Sequentially, it rose 6.6% from the prior quarter. Over 3 fiscal years it compounded at +18.2% a year.
Context
- Net income amounted to 4342.4% of revenue in FY2025, down 2224.2 pp from a year earlier.
- Net income grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 8 analysts of -$139.86M (-30.5%) for the fiscal year ending Dec 2026, a slowdown from the +2.7% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$49.12M+6.6% QoQ
- Last fiscal yearDec 2025
- -$201.14M+2.7% YoY
- LTMMar 2026
- -$198.37M-1.8% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -5.3% | -13.0% | -7.7 pp |
| 1 year | +2.7% | -30.5% | -33.2 pp |
| 3-year CAGR | +18.2% | -14.0% | -32.2 pp |
| 5-year CAGR | -11.7% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (201.14M) USD
- Year-over-year change
- -2.7%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (201.14M) | -2.7% |
| FY2024 | 2024-12-31 | (195.88M) | +1.1% |
| FY2023 | 2023-12-31 | (198.13M) | -62.6% |
| FY2022 | 2022-12-31 | (121.82M) | +26.3% |
| FY2021 | 2021-12-31 | (165.37M) | — |
Net Income vs competitors
How PRME compares with its peers on the latest reported figures
- PRME's LTM Mar 2026 net income of $198.37M is the 3rd largest of the 7 companies compared; the peer median is $121.09M.
- Its year-over-year change of -1.8% is the 2nd highest of 7, against a peer median of -8.2%.
- Net income amounts to 4917.6% of revenue for PRME, versus a peer median of 757.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $500.92M | -4.8% | +3.1% | 757.9% | |
| LTM Sep 2026 | $456.14M | -6.6% | -3.6% | 1812.1% | |
| LTM Mar 2026 | $198.37M | -1.8% | +18.2% | 4917.6% | |
| LTM Mar 2026 | $133.22M | -9.9% | +14.2% | 1189.1% | |
| LTM Mar 2026 | $108.95M | -56.6% | -10.1% | 281.6% | |
| LTM Jun 2026 | $85.43M | -78.6% | -34.8% | 54.7% | |
| LTM Mar 2026 | $69.71M | +24.0% | +3.3% | — | |
SCTXScribe Therapeutics Inc. | — | — | — | — | — |
| Peer median (excluding PRME) | $121.09M | -8.2% | -0.3% | 757.9% | |
Competitors are the stored peer set for PRME. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (165.37M) | (121.82M) | (198.13M) | (195.88M) | (201.14M) |
| Depreciation & Amortization | 568K | 2.22M | 4.65M | 6.13M | 5.38M |
| Deferred Income Tax | (624K) | (964K) | (279K) | 0 | 0 |
| Stock-Based Compensation | 1.75M | 6.46M | 13.91M | 26.07M | 29.27M |
| Change in Working Capital | 31.18M | (35.4M) | 2.65M | 31.08M | (5.34M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.19M | 2.46M | 9.14M | (5.26M) | 996K |
| Other Working Capital | 29.99M | (37.86M) | (6.49M) | 36.33M | (6.34M) |
| Other Non-Cash Items | 98.42M | 17.68M | 11.79M | 9.75M | 9.27M |
| Operating Cash Flow | (34.08M) | (131.83M) | (165.41M) | (122.87M) | (162.56M) |
| Capital Expenditures | (4.15M) | (16.1M) | (8.72M) | (7.29M) | (4.53M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (81.98M) | (123.34M) | (104.95M) | (129.45M) | (205.41M) |
| Sales of Investments | 13M | 93M | 132.56M | 204.2M | 101.18M |
| Other Investing Activities | (496K) | (665K) | (170K) | 1M | 0 |
| Investing Cash Flow | (73.63M) | (47.1M) | 18.71M | 68.46M | (108.76M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 270.36M | 185.32M | 655K | 170.14M | 139.51M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (1.09M) | (3.82M) | 0 | 25.74M | 12M |
| Financing Cash Flow | 269.28M | 181.49M | 655K | 195.88M | 151.51M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 161.57M | 2.57M | (146.05M) | 141.47M | (119.82M) |
| Free Cash Flow | (38.23M) | (147.92M) | (174.14M) | (130.16M) | (167.1M) |
Prime Medicine, Inc.
NASDAQ:PRME
Intrinsic Alpha fair value
Locked
Current Price
$3.82
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.